Argenx (ARGX)
(Delayed Data from NSDQ)
$371.02 USD
+8.86 (2.45%)
Updated May 31, 2024 04:00 PM ET
Pre-Market: $370.57 -0.45 (-0.12%) 8:12 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$371.02 USD
+8.86 (2.45%)
Updated May 31, 2024 04:00 PM ET
Pre-Market: $370.57 -0.45 (-0.12%) 8:12 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
argenex SE (ARGX) Surges 27.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
argenex SE (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
All You Need to Know About argenex SE (ARGX) Rating Upgrade to Buy
by Zacks Equity Research
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Editas (EDIT) Soars 20.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Geron (GERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on updates on Geron's (GERN) lead pipeline candidate when it reports its fourth-quarter earnings.
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance
by Zacks Equity Research
Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the company's guidance fell short of Wall Street expectations.
argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why
by Zacks Equity Research
Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.
Why Earnings Season Could Be Great for argenx (ARGX)
by Zacks Equity Research
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Sundeep Ganoria
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
argenex SE (ARGX) Upgraded to Buy: Here's Why
by Zacks Equity Research
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
by Zacks Equity Research
Here is how Lantheus Holdings (LNTH) and argenex SE (ARGX) have performed compared to their sector so far this year.
Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Here's Why argenex SE (ARGX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does argenex SE (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug
by Zacks Equity Research
Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.
Best Momentum Stocks to Buy for August 3rd
by Zacks Equity Research
SSB, XOM and ARGX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 3, 2022.
Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and argenex SE (ARGX) have performed compared to their sector so far this year.
Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.
Halozyme's (HALO) ENHANZE Drives Stock: Rally to Continue?
by Zacks Equity Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
by Zacks Equity Research
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?
by Zacks Equity Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.